THE 60-SECOND GUIDE
AOD-9604
Controlled human trials · larger obesity trial negative.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
AOD-9604 is a modified growth-hormone fragment developed as a potential obesity treatment. It was intended to separate fat-related activity from other growth-hormone effects, but that design goal did not establish clinically meaningful weight loss. [1]
Potential benefits
Investigated as a modified growth-hormone fragment for obesity. Designed to explore fat-metabolism effects without full GH activity. [1]
Evidence & its limits
Human trials exist, so describing AOD-9604 as merely untested misses the central finding: the larger oral trial failed its weight-loss endpoint. Those data also do not establish benefit or safety for subcutaneous products sold for fat loss. [1]
Risks & unknowns
No FDA-approved obesity indication. Clinical development did not establish the broad claims now made online. [1]
Status & scope
No FDA-approved obesity indication. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.